Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|June 27, 2009
A prognostic scoring system for adult patients less than 60 years of age with acute lymphoblastic leukemia in first relapseAnjali Advani, Tao Jin, Brian Bolwell, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2010
Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemiaDavid Rizzieri, Samantha LoRusso, William Tse, et al.
Cancer|August 29, 2007
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemiaRachid Baz, Cristina Rodriguez, Alex Z Fu, et al.
Leukemia & Lymphoma|August 19, 2007
White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemiaHyo Sook Han, Lisa A Rybicki, Karl Thiel, et al.
Leukemia Research|August 31, 2007
Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemiaCristina P Rodriguez, Rachid Baz, Rony Abou Jawde, et al.
Leukemia Research|August 11, 2010
Race and intensity of post-remission therapy in acute myeloid leukemiaAnna K Brady, Alex Z Fu, Marc Earl, et al.
Leukemia & Lymphoma|August 11, 2011
Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panelWendy Stock, Dan Douer, Daniel J DeAngelo, et al.
Cancer|June 22, 2010
Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemiaNelli Bejanyan, Alex Z Fu, Aleksandr Lazaryan, et al.
Cancer|October 21, 2010
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaMikkael A Sekeres, Jaroslaw P Maciejewski, Harry P Erba, et al.
Cancer|December 20, 2011
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)Nelli Bejanyan, Ramon V Tiu, Azra Raza, et al.
Pageof 6